TIDMIMM
RNS Number : 4745Q
Immupharma PLC
28 June 2022
RNS: RELEASE 28 June 2022
ImmuPharma PLC
("ImmuPharma" or the "Company")
2022 RESULT OF ANNUAL GENERAL MEETING - ALL RESOLUTIONS
PASSED
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and
development company, held its AGM earlier today. The Company is
pleased to announce that all resolutions were duly passed, details
of which are contained in the table below.
ImmuPharma's Chairman & CEO, Tim McCarthy said: "We are
delighted to have had such overwhelming support from right across
our shareholder base. This includes corporate, institutional and
long-term private shareholders, in respect to all of the AGM
resolutions. The support for the re-appointment of the new Board,
an integral part of the management restructuring, successfully
completed in August last year, being part of the resolutions being
approved.
Importantly, we also announced yesterday, a key progress update
on our lead programme, Lupuzor(TM). Our partner, Avion
Pharmaceuticals, who is also a major supportive shareholder, has
confirmed that having met all the Food and Drug Administration's
("FDA") requirements, they have sought final guidance from the FDA,
as they actively prepare for the start of the international Phase 3
trial of Lupuzor(TM) in Lupus patients. This is a key inflection
point for the positive progress of Lupuzor(TM) towards becoming a
first line therapy to many Lupus sufferers globally.
On behalf of the new Board, I would like to thank all our
shareholders and collaborators for their continued belief in
ImmuPharma."
Resolution For % For Against % Against Withheld
1. To receive the accounts
of the Company for the
year ended 31 December
2021 together with the
reports thereon of the
directors and auditors
of the Company 53,394,853 99.14 463,666 0.86 837,178
----------- ------ -------- ---------- ---------
2. To re-appoint Tim McCarthy
as a director of the Company 53,310,582 98.99 542,318 1.01 842,797
----------- ------ -------- ---------- ---------
3. To re-appoint Dr Tim
Franklin as a director
of the Company 53,300,349 99.00 540,213 1.00 855,135
----------- ------ -------- ---------- ---------
4. To re-appoint Dr Sanjeev
Pandya as a director of
the Company 53,304,688 99.00 535,874 1.00 855,135
----------- ------ -------- ---------- ---------
5. To re-appoint Lisa
Baderoon as a director
of the Company 53,304,363 99.00 536,199 1.00 855,135
----------- ------ -------- ---------- ---------
6. To re-appoint Nexia
Smith & Williams as auditors
of the Company 53,280,466 99.02 527,057 0.98 888,174
----------- ------ -------- ---------- ---------
7. That subject to the
passing of resolution
10, each ordinary share
of GBP0.10 in the capital
of the Company be sub-divided
into one ordinary share
of GBP0.01 each and one
deferred share of GBP0.09
each 53,000,307 98.47 821,831 1.53 873,559
----------- ------ -------- ---------- ---------
8. That the Directors
be authorised for the
purpose of Section 551
of the Companies Act 2006
(the "Act") to allot shares
on the basis as set out
in the Notice of Meeting.
Special Resolution 52,999,192 98.58 765,320 1.42 931,185
----------- ------ -------- ---------- ---------
9. That, subject to the
passing of Resolution
8, the Directors are hereby
empowered pursuant to
section 571 of the Act
to allot equity securities
on the basis as set out
in the Notice of Meeting 52,972,066 98.53 792,446 1.47 931,185
----------- ------ -------- ---------- ---------
10. That, subject to the
passing of resolution
7, the articles of association
of the Company be amended
as set out in the Notice
of Meeting 52,992,957 98.56 772,458 1.44 930,282
----------- ------ -------- ---------- ---------
As at the date of the AGM, the number of issued ordinary shares
of the Company was 284,984,933 shares, which was the total number
of shares entitling the holders to attend and vote for or against
all resolutions. In accordance with the Company's Articles of
Association, every member has one vote for every share held. Votes
withheld are not votes in law and have not been counted in the
calculation of the proportion of vote "for" or "against" a
resolution. Proxy appointments which gave discretion to the
Chairman have been included in the "for" total.
This announcement contains inside information as stipulated
under the UK version of the Market Abuse Regulation no 596/2014
which is part of English law by virtue of the European (withdrawal)
Act 2018, as amended. On publication of this announcement via a
regulatory information service, this information is considered to
be in the public domain.
Ends
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chairman and Chief Executive
Officer +44 (0) 207 206 2650
Lisa Baderoon, Head of Investor Relations
& Non-Executive Director + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 36 8 3550
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes, Bob Pountney +44 (0) 20 3650 3650
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical
company that discovers and develops peptide-based therapeutics. The
Company's portfolio includes novel peptide therapeutics for
autoimmune diseases and anti-infectives. The lead program,
Lupuzor(TM), within our P140 platform, is a first-in class
autophagy immunomodulator which is in Phase 3 for the treatment of
Lupus, a debilitating and potentially life threatening auto immune
disease. Preclinical analysis suggests therapeutic activity for
many other autoimmune diseases targeted through our P140 platform,
that share the same autophagy mechanism of action.
For additional information about ImmuPharma please visit
www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code:
213800VZKGHXC7VUS895.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGDZGZVGRMGZZM
(END) Dow Jones Newswires
June 28, 2022 06:42 ET (10:42 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024